| Identification | Back Directory | [Name]
A-130A | [CAS]
51257-84-2 | [Synonyms]
A-130A
Lenoremycin
Antibiotic A 130A
Antibiotic Ro 21 6150
6-Nonenoic acid, 2,4,6-trimethyl-5-oxo-8-[(2S,2'R,4'S,5R,5'R,7S,7'R,9R,10R,10'R)-2,4',10,10'-tetramethyl-2'-[(2S,3S,5R,6R)-tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl]-9-[[(2R,5S,6R)-tetrahydro-5-methoxy-6-methyl-2H-pyran-2-yl]oxy][2,7'-bi-1,6-dioxaspiro[4.5]dec]-7-yl]-, (2S,4R... | [Molecular Formula]
C47H78O13 | [MOL File]
51257-84-2.mol | [Molecular Weight]
851.11 |
| Chemical Properties | Back Directory | [Boiling point ]
693.44°C (rough estimate) | [density ]
1.0441 (rough estimate) | [refractive index ]
1.5940 (estimate) | [pka]
4.59±0.21(Predicted) |
| Hazard Information | Back Directory | [Uses]
Lenoremycin (Ro 21-6150) is a microbial metabolite. Lenoremycin decreases β-catenin and cyclin D1 proteins levels. Lenoremycin decreases cancer stem cells (CSCs) populations via inducing reactive oxygen species production[1]. | [References]
[1] Ikeda H, et al. Identification of the polyether ionophore lenoremycin through a new screening strategy for targeting cancer stem cells. J Antibiot (Tokyo). 2022 Dec;75(12):671-678. DOI:10.1038/s41429-022-00571-1 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|